Epic Sciences

03.18.2019 Back to News Listings

Test Predicts Resistance to Hormonal Therapy in Prostate Cancer - Validation study confirms assist in decision-making

A blood test that measures the spliced variant of an androgen receptor called AR-V7 in circulating tumor cells successfully predicted resistance to commonly used hormonal therapy agents in advanced prostate cancer, a validation study confirmed.

In the multicenter PROPHECY trial, researchers found that the use of two blood-based assays for measuring AR-V7 -- the Johns Hopkins modified-AdnaTest CTC AR-V7 mRNA assay and the Epic Sciences CTC nuclear AR-V7 protein assay -- demonstrated that AR-V7 positivity is associated with resistance to the androgen receptor (AR) pathway inhibitors abiraterone and enzalutamide.

"We confirmed that AR-V7, if positive, was associated with a lack of benefit with these therapies – a very low probability of a response to these hormone drugs, a short time to progression, and very low survival for men who test positive," Andrew Armstrong, MD, Duke Cancer Institute, told MedPage Today.

Read the full article on MEDPAGE TODAY.